What is the current recommended treatment for herpes zoster (shingles)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Current Treatment for Shingles (Herpes Zoster)

Start oral antiviral therapy within 72 hours of rash onset with acyclovir, valacyclovir, famciclovir, or brivudin (where available), as early treatment significantly reduces acute pain, accelerates healing, and may decrease the risk of postherpetic neuralgia.

Antiviral Therapy

First-Line Oral Antivirals

The cornerstone of shingles treatment is systemic antiviral medication, which should be initiated as soon as possible, ideally within 72 hours of rash appearance 1, 2. The following agents have equivalent efficacy and safety profiles:

  • Acyclovir: 800 mg orally 5 times daily for 7-10 days 1, 2
  • Valacyclovir: 1 g orally 3 times daily for 7 days 1, 2
  • Famciclovir: 500 mg orally 3 times daily for 7 days 1, 2
  • Brivudin (where available): 125 mg orally once daily for 7 days 2

Valacyclovir and famciclovir offer improved oral bioavailability compared to acyclovir, allowing for less frequent dosing and potentially better patient adherence 1. Brivudin has markedly higher anti-VZV potency and requires only once-daily dosing, with no nephrotoxic properties 2.

Urgent Indications for Antiviral Therapy

Systemic antiviral treatment is urgently indicated in the following situations 2:

  • All patients ≥50 years of age
  • Herpes zoster involving the head and neck area (especially zoster ophthalmicus)
  • Severe herpes zoster on trunk or extremities
  • Immunocompromised patients at any age
  • Patients with severe atopic dermatitis or eczema

Intravenous Therapy

For severe disease requiring hospitalization (disseminated infection, encephalitis, pneumonitis, hepatitis, or acyclovir-resistant strains in immunocompromised patients), use acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days 3.

Pain Management

The primary goal of herpes zoster treatment is achieving painlessness 2. Pain management should be initiated concurrently with antiviral therapy:

Acute Pain Control

  • Appropriately dosed analgesics combined with a neuroactive agent (e.g., amitriptyline) are highly effective when given with antiviral therapy 2
  • Corticosteroids may shorten the duration and severity of acute zoster pain, though they have minimal effect on preventing postherpetic neuralgia 2

Postherpetic Neuralgia (PHN) Treatment

For pain persisting ≥90 days after acute herpes zoster 4:

  • Topical agents: Lidocaine or capsaicin 4
  • Oral medications: Gabapentin, pregabalin, or tricyclic antidepressants 4, 5
  • Note that PHN treatment often provides poor relief, with up to half of patients achieving less than 50% pain reduction 6

Special Populations

Immunocompromised Patients

  • May require higher doses of antivirals (e.g., acyclovir 400 mg orally 3-5 times daily) 3
  • Prolonged treatment courses may be necessary 3
  • For acyclovir-resistant strains: foscarnet 40 mg/kg IV every 8 hours or topical cidofovir gel 1% daily for 5 days 3
  • HIV-infected patients should be monitored closely, as healing may be slower and treatment failures can occur 3

Pregnancy

  • Oral acyclovir can be used for first clinical episodes during pregnancy 3
  • IV acyclovir is indicated for life-threatening maternal HSV infection (disseminated infection, encephalitis, pneumonitis, hepatitis) 3
  • Current registry findings do not indicate increased risk for major birth defects with acyclovir treatment 3

Important Clinical Considerations

Timing is Critical

Peak viral titers occur within the first 24 hours after lesion onset 3. Since the natural healing process begins within this timeframe, treatment must be initiated as early as possible to ensure optimal therapeutic benefit 3.

Topical Therapy

Avoid topical acyclovir as it is substantially less effective than systemic therapy 3. Topical antivirals are not effective prophylactically because they cannot reach the site of viral reactivation in the dorsal root ganglia 3.

Prevention

For patients ≥50 years old, vaccination is the most effective preventive measure 4. The recombinant zoster vaccine (RZV/Shingrix) is preferred over the live attenuated vaccine (ZVL/Zostavax) due to superior efficacy and durability 3, 7.

References

Research

Recommendations for the management of herpes zoster.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007

Research

Herpes zoster guideline of the German Dermatology Society (DDG).

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2003

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of herpes zoster and post-herpetic neuralgia now and in the future.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010

Research

Prevention of herpes zoster pain.

Pain management, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.